DOCSLIB.ORG

Experimental Plasmacytomas in Relation to Human Multiple Myeloma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Experimental Plasmacytomas in Relation to Human Multiple Myeloma A n n a l s o f C l i n i c a l a n d L a b o r a t o r y S c i e n c e , Vol. 4, No. 3 Copyright © 1974, Institute for Clinical Science Experimental Plasmacytomas in Relation to Human Multiple Myeloma HENRY A. AZAR, M.D. Laboratory Service, VA Hospital, Tampa, FL 33612 and Department of Pathology, University of South Florida College of Medicine, Tampa, FL 33620 ABSTRACT Among animal models of plasma cell tumors, that induced in BALB/c mice by means of intraperitoneal injections of oils remains the most reproducible and the most intensively studied. The BALB/c oil-induced and transplantable plasmacytomas resemble hu­ man myeloma in their ability to produce a monoclonal immunoglobulin or Bence Jones protein. Bence Jones type nephrosis in BALB/c mice closely mimics its human counterpart. There are also similarities in background of immunodeficiency and in antigen-binding affinity of monoclonal immuno­ globulins, as well as in interesting interrelationships with malignant lympho­ mas. Unlike the BALB/c tumor model, human myeloma is, however, prin­ cipally a skeletal disease, not a gut-oriented or peritoneal plasmacytoma. The intriguing presence of intracistemal type A virus-like particles in BALB/c plasmacytoma cells and their absence in human myeloma is another major difference between the two forms of growth. The pathogenesis of human myeloma remains obscure but the availability of experimental plasmacytoma models offers a means of systematically analyz­ ing events leading to the neoplastic transformation of antibody-forming cells. Introduction other in a mesenteric lymph node.4 These In addition to man, several mammals spontaneous tumors constitute uncommon were observed to develop plasma cell tu­ though fascinating events. Plasma cell tu­ mors spontaneously. For example, the mul­ mors can be induced in a predictable tiple myeloma of the dog resembles human fashion in mice, particularly the BALB/c myeloma and features osteolytic lesions, strain. The reader is referred to Potters monoclonal gammapathy and Bence Jones comprehensive review of experimental type nephropathy.16 Multiple myeloma has plasma cell tumors of mice.18 been also observed in a cat.10 Two plasma­ The aim of this presentation is to outline cytomas have been described in the Syrian the characteristics of induced plasma cell hamster: one arose in the neck and the tumors of mice, particularly the BALB/c 1 5 8 AZAR Thelma Dunn6 reported in 1954 that sev­ TA BLE I eral mice had an inflammatory lesion of the P lasmacytomas o f M i c e cecum. In some of these lesions, plasma­ cytic neoplasms arise in the ileocecal region "Plasma Cell Leukemia" in Street and in relation to the cecitis. A later sur­ Strain Mice 1951 vey7 indicated that ileocecal plasmacyto­ Rask-Nielsen, R. and Gormsen, H. mas were commoner in C3H mice than in Ileocecal Plasmacytomas of C3H other strains and that they occurred more Mice 1954 frequently in old mice. Dunn, T .B . Murphy15 described in 1963 a new in- bred strain of mice (SJL/J) with a high Induced Peritoneal Plasmacytomas incidence of reticulum cell neoplasms. (BALB/c Mice) 1960 Fifty percent of these neoplasms were asso­ Potter, M. and Robertson, C.L. ciated with “paraproteinemia.” Unfortu­ Plasma Cell Tumors in NZB and nately, the production of monoclonal im­ NZBX BALB/c Mice 1966 munoglobulin has been unstable following Werner, N. et al transplantation of these tumors. Fujinaga et al11 transmitted “SJL/J disease” to Pleomorphic Lymphomas in SJL/J BALB/c mice with cell-free extracts. They Mice 1969 succeeded in producing reticulum cell neo­ Murphy, E.D. plasms but not plasmacytomas. Plasmacytomas are successfully induced by intraperitoneal injection of oily sub­ strain, and relate these to the problem of stances in BALB/c and NZB mice as well human myeloma. as in (BALB/c X NZB) FI hybrids.18 The NZB strain is also genetically susceptible Plasmacytomas of Mice to the development of nephritis and auto­ immune phenomena. The oil-induced plas­ The more important experimental plasma macytomas are by far the most widely cell tumor models of mice are listed in studied model of immunoglobulin-produc­ table I. Although the reader’s attention will ing experimental tumors. Primary and be drawn to the oil-induced peritoneal transplanted BALB/c plasmacytomas are plasmacytomas of BALB/c mice, a brief under active investigation in our labora­ outline of other models of plasmacytic and tory. They are considered to be a depend­ related lymphoreticular growths is in order. able and readily available source of tumor The “plasma cell leukemia” in Street that strikingly resembles human myeloma. strain mice described by Rask-Nielsen and and Gormsen20 in 1951 has the morphologic features of reticulum cell sarcoma with Oil-Induced Plasmacytomas plasmacytic differentiation. In later studies, of BALB/c Mice (CBA X DBA/2) FI hybrids, including In an experiment designed to test the mice injected with a variety of cell-free survival of allogeneic grafts as well as the material, developed a high incidence of behavior of M.T.A. virus, Merwin and Al- “plasma cell leukemia.”21 Several of the gire13 implanted estrogen-treated BALB/c transplanted reticular and plasmacytic neo­ mice with Millipore diffusion chambers plasms transplanted by Ebbesen and Rask- containing C3H mammary tumor. Six Nielsen9 were associated with “parapro­ months later, the BALB/c recipients de­ teinemia” and amyloidosis. veloped hemorrhagic ascites owing to per­ EXPERIMENTAL PLASMACYTOMAS 1 5 9 itoneal plasma cell tumor or fibrosarcoma.8 T A B L E II Empty chambers, leucite discs or borings N e o p l a s m s F o u n d i n B A L B / c M i c e F o l l o w i n g also caused the development of plasma cell I ntraperitoneal I n j e c t i o n o f A d j u v a n t tumors.14 Subsequently, Potter and Boyce19 reported that plasma cell tumors could be Con- induced by means of intraperitoneal injec­ Ex— v en - tions of mineral oil alone or adjuvant mix­ Germ- Germ- t i o n - tures. A variety of oils have been tested f r e e f r e e a l since. More recently, pristane (2,6,10,14- tetramethylpentadecane) was found to be Plasma cell 2 24 28 an extremely potent inducer of plasmacy­ tumor tomas in BALB/c mice.1 Pleomorphic 16 3 4 The experimental model of oil-induced reticulum plasmacytomas has been described in de­ cell sarcoma Monomorphic 7 1 1 tail elsewhere.18 This model has been ex­ reticulum tensively exploited to demonstrate the cell sarcoma chain of events leading to the synthesis of Mixed reticulum 2 specific classes and types of immunoglob­ cell sarcoma ulin. The same model has been used to Lymphocytic 1 study the effect of hereditary and hormonal ■ neoplasm Pulmonary 2 2 influences on the induction of plasma cell adenoma tumors. Since the majority of oil-induced Myoepithelioma 1 1 1 plasmacytomas are immunoglobulin-form­ Uterine adenoma 1 ing tumors, the role of intestinal bacteria R eticu lar 3 4 and bacterial antigens on the differentia­ hyperplasia tion of plasmacytomas has also been exten­ (no tumor) —— — sively investigated. T otal 33 31 40 M o r p h o l o g ic F e a t u r e s The sequence of events following the After Mclntire and Princler: intraperitoneal injections of mineral oil or Immunology 17:481, 1969. pristane starts with an acute inflammatory reaction which first covers the peritoneal readily transplanted. Primary or induced surfaces and surrounds oil droplets. No plasmacytomas may vary in size from one plasma cells or lymphocytes are noted at mm to two or three cm in greater diameter. this stage. At a later period, from one to Transplantable plasmacytomas grow into three months after the initial injection of BALB/c hosts or BALB/c hybrids to attain the oil, individual or small clusters of a size of two to three cm at which point plasma cells begin to form within the oil they frequently ulcerate or kill their host granulomas. From five months to eight as a result of bowel strangulation or of months following the injection of the oil, Bence Jones type nephrosis. larger clusters of plasma cell precursors are observed. Such aggregates are particularly Bence Jones type nephrosis with typical noted under the diaphragm and over the hard, fragmented or laminated casts are surface of the liver. Ultimately, these gran­ seen in animals bearing k or A polypeptide- ules grow into small tumors which become producing tumors. Metastases are not seen autonomous plasmacytomas that can be as a rule in primary or induced plasma- 1 6 0 AZAR cytomas but do develop in animals bearing ulum cells except for their basophilic and large transplanted plasmacytomas. pyroninophilic cytoplasm. Seldom do they Plasmacytoma cells often resemble retie- appear to be frankly plasmacytic. Trans- F i c u i i e 1. Electron micrograph of portion of Pristane-induced plasmacytoma cell illustrating a large number of intracisternal type A particles. Some of these appear to be budding from the endoplasmic reticulum lining the cisternae. Uranyl acetate and lead citrate, X 51,000. EXPERIMENTAL PLASMACYTOMAS 1 6 1 planted plasmacytomas are even more ana­ plastic looking than primary plasma cell tumors. On electron microscopy, plasma­ cytoma cells generally display an abun­ H0PC1 S dance of rough endoplasmic reticulin as well as free polyribosomes. RPC5 S T y p e A — I ntracisternal P a r t i c l e s Whereas the normal lymphoid tissue of TEPC183 S the BA LB/c mouse may contain type B or C RNA viruses with well-formed nucleoids, M0PC321 S one does not readily observe type A par­ ticles in either lymphocytes or plasma cells.
Load more

Recommended publications
  • Extraosseous Plasmacytoma with an Aggressive Course Occurring Solely in the CNS
    bs_bs_banner Neuropathology 2013; 33, 320–323 doi:10.1111/j.1440-1789.2012.01352.x Case Report Extraosseous plasmacytoma with an aggressive course occurring solely in the CNS William Wu, Whitney Pasch, Xiaohui Zhao and Sherif A. Rezk Department of Pathology & Laboratory Medicine, University of California, Irvine (UCI), Irvine, California, USA Extraosseous (extramedullary) plasmacytoma is a rela- defined as the presence of monoclonal plasma cells in the tively indolent neoplasm that constitutes 3–5% of all CSF during the course of plasma cell myeloma.3 In addition, plasma cell neoplasms. Rare cases have been reported to few cases of extraosseous plasmacytomas involving the truly occur in the CNS and not as an extension from a nasal nasal septum or sinuses have been reported to extend into lesion. EBV expression in plasma cell neoplasms has been the CNS.4 Given that involvement of the CNS as the initial reported in very few cases that are mainly post-transplant and sole presentation of plasma cell neoplasms is exceed- or occurring in severely immunosuppressed patients. ingly rare and their association with EBV has not previously We report a case of extraosseous plasmacytoma with been well-documented,we present an unusual case of extra- an aggressive course in an HIV-positive individual that osseous plasmacytoma expressing EBV and presenting in occurred solely in the CNS, showing EBV expression by in the CNS of a 40-year-old HIV-positive man. situ hybridization, and presenting as an intraparenchymal mass as well as in the CSF. CASE REPORT Key words: aggressive, central nervous system (CNS), A 40-year-old HIV-positive Hispanic man was admitted to Epstein–Barr virus (EBV), human immunodeficiency virus the Emergency Room for altered mental status, fever, (HIV), plasmacytoma.
    [Show full text]
  • Up-Date on Solitary Plasmacytoma and Its Main Differences with Multiple Myeloma P
    Experimental Oncology 27, 7-12, 2005 (March) 7 Exp Oncol 2005 27, 1, 7-12 UP-DATE ON SOLITARY PLASMACYTOMA AND ITS MAIN DIFFERENCES WITH MULTIPLE MYELOMA P. Di Micco1,*, B. Di Micco2 1Thrombosis center, Instituto Clinico Humanitas, Milan, Italy 2Clinical Chemistry, University of Sannio, Benevento, Italy Solitary plasmacytoma is plasma cell neoplasm. It is a localized bone disease and for this reason it is different from multiple myeloma (systemic plasma cell neoplasm). Sometimes, solitary plasmacytoma precedes a following multi- ple myeloma. Clinical findings of solitary plasmacytoma are related to the univocal localization on damaged bone, while laboratory findings could be similar to multiple myeloma (i.e. M component, kidney dysfunction, blood calcium alterations, increased β-2-microglobulin). However, during a solitary plasmacytoma, laboratory findings could not be present contemporaneously such clinical complications (i.e. kidney failure, immunological disorders with a trend toward infectious disease and/or autoimmunity, neurological disorders, haematological disorders, amyloidosis, POEMS syndrome). These raise the reason because solitary plasmacytoma has better prognosis compared to multiple myeloma. Key Words: solitary plasmacytoma, multiple myeloma. General information damages are principally related to light chains and are Plasmacytoma, a clonal neoplastic disorder of bone quickly eliminated representing the Beence-Jones pro- marrow that originates from plasma cells, the last mat- tein in the urine [9, 10]. Moreover, immunoglobulin pro- uration stage of B lymphocytes [1-2], may appear as duced by plasmacytoma may be insoluble if cold tem- three different diseases: multiple myeloma (systemic perature is present, so causing a cryoglobulinemia [5, disease), extramedullary plasmacytoma and solitary 11], in particular if a chronic C viral hepatitis is associ- plasmacytoma (localized bone disease) [3].
    [Show full text]
  • Spotlight on Ixazomib: Potential in the Treatment of Multiple Myeloma Barbara Muz Washington University School of Medicine in St
    Washington University School of Medicine Digital Commons@Becker Open Access Publications 2016 Spotlight on ixazomib: Potential in the treatment of multiple myeloma Barbara Muz Washington University School of Medicine in St. Louis Rachel N. Ghazarian Washington University School of Medicine in St. Louis Monica Ou Washington University School of Medicine in St. Louis Micha J. Luderer Washington University School of Medicine in St. Louis Hubert D. Kusdono Washington University School of Medicine in St. Louis See next page for additional authors Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs Recommended Citation Muz, Barbara; Ghazarian, Rachel N.; Ou, Monica; Luderer, Micha J.; Kusdono, Hubert D.; and Azab, Abdel K., ,"Spotlight on ixazomib: Potential in the treatment of multiple myeloma." Drug Design, Development and Therapy.2016,10. 217-226. (2016). https://digitalcommons.wustl.edu/open_access_pubs/5207 This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact [email protected]. Authors Barbara Muz, Rachel N. Ghazarian, Monica Ou, Micha J. Luderer, Hubert D. Kusdono, and Abdel K. Azab This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/open_access_pubs/5207 Journal name: Drug Design, Development and Therapy Article Designation: Review Year: 2016 Volume:
    [Show full text]
  • POEMS Syndrome and Small Lymphocytic Lymphoma Co-Existing in the Same Patient: a Case Report and Review of the Literature
    Open Access Annals of Hematology & Oncology Special Article - Hematology POEMS Syndrome and Small Lymphocytic Lymphoma Co-Existing in the Same Patient: A Case Report and Review of the Literature Kasi Loknath Kumar A1,2*, Mathur SC3 and Kambhampati S1,2* Abstract 1Department of Hematology and Oncology, Veterans The coexistence of B-cell Chronic Lymphocytic Leukemia/Small Affairs Medical Center, Kansas City, Missouri, USA Lymphocytic Lymphoma (CLL/SLL) and Plasma Cell Dyscrasias (PCD) has 2Department of Internal Medicine, Division of rarely been reported. The patient described herein presented with a clinical Hematology and Oncology, University of Kansas Medical course resembling POEMS syndrome. The histopathological evaluation Center, Kansas City, Kansas, USA of the bone marrow biopsy established the presence of an osteosclerotic 3Department of Pathology and Laboratory Medicine, plasmacytoma despite the absence of monoclonal protein in the peripheral Veterans Affairs Medical Center, Kansas City, Missouri, blood. Cytochemical analysis of the plasmacytoma demonstrated monotypic USA expression of lambda (λ) light chains, a typical finding associated with POEMS *Corresponding authors: Kambhampati S and Kasi syndrome. A subsequent lymph node biopsy performed to rule out Castleman’s Loknath Kumar A, Department of Internal Medicine, disease led to an incidental finding of B-CLL/SLL predominantly involving the Division of Hematology and Oncology, University of B-zone of the lymph node. The B-CLL population expressed CD19, CD20, CD23, Kansas Medical Center, Kansas City, 2330 Shawnee CD5, HLA-DR, and kappa (κ) surface light chains. To the best of our knowledge, Mission Parkway, MS 5003, Suite 210, Westwood, KS, a simultaneous manifestation of CLL/SLL and POEMS has not been previously 66205, Kansas, USA, Tel: 9135886029; Fax: 9135884085; reported in the literature.
    [Show full text]
  • Solitary Plasmacytoma: a Review of Diagnosis and Management
    Current Hematologic Malignancy Reports (2019) 14:63–69 https://doi.org/10.1007/s11899-019-00499-8 MULTIPLE MYELOMA (P KAPOOR, SECTION EDITOR) Solitary Plasmacytoma: a Review of Diagnosis and Management Andrew Pham1 & Anuj Mahindra1 Published online: 20 February 2019 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of Review Solitary plasmacytoma is a rare plasma cell dyscrasia, classified as solitary bone plasmacytoma or solitary extramedullary plasmacytoma. These entities are diagnosed by demonstrating infiltration of a monoclonal plasma cell population in a single bone lesion or presence of plasma cells involving a soft tissue mass, respectively. Both diseases represent a single localized process without significant plasma cell infiltration into the bone marrow or evidence of end organ damage. Clinically, it is important to classify plasmacytoma as having completely undetectable bone marrow involvement versus minimal marrow involvement. Here, we discuss the diagnosis, management, and prognosis of solitary plasmacytoma. Recent Findings There have been numerous therapeutic advances in the treatment of multiple myeloma over the last few years. While the treatment paradigm for solitary plasmacytoma has not changed significantly over the years, progress has been made with regard to diagnostic tools available that can risk stratify disease, offer prognostic value, and discern solitary plasmacytoma from quiescent or asymptomatic myeloma at the time of diagnosis. Summary Despite various studies investigating the use of systemic therapy or combined modality therapy for the treatment of plasmacytoma, radiation therapy remains the mainstay of therapy. Much of the recent advancement in the management of solitary plasmacytoma has been through the development of improved diagnostic techniques.
    [Show full text]
  • Primary Plasma Cell Leukemia: a Practical Approach to Diagnosis and Clinical Management
    PRIMARY PLASMA CELL LEUKEMIA: A PRACTICAL APPROACH TO DIAGNOSIS AND CLINICAL MANAGEMENT Primary Plasma Cell Leukemia: A Practical Approach to Diagnosis and Clinical Management Wilson I. Gonsalves, MD Abstract clonal plasma cells. Although Gluzinski and Reichenstein were the 1 Primary plasma cell leukemia (pPCL) represents a rare first to describe a case of PCL back in 1906, it was Kyle and Noel but most aggressive form of multiple myeloma. Its who went on to define it as the presence of plasma cells consisting leukemic clinical characteristics, as seen by the presence of more than 20% of the differential white count in the peripheral of circulating clonal plasma cells, its unique molecular blood, or an absolute plasma cell peripheral blood count of greater 9 2 and cytogenetic aberrations, and its exceedingly poor than 2.0 x 10 cells/L. If PCL is detected at diagnosis de novo survival outcomes set it apart from traditional multiple without a prior history of MM, it is considered primary plasma cell myeloma. Recent advances in the utilization of novel leukemia (pPCL). HoWever, if PCL arises in a patient with a known agents and high-dose chemotherapy in the upfront man- history of MM, it is considered secondary PCL (sPCL). The con- agement of patients with pPCL is finally bearing fruit in dition occurs as a progressive event of the disease in 1% to 4% of 3 terms of improving survival outcomes, albeit modestly. patients with MM. With the improvement in survival experienced 4 Early recognition of pPCL in a newly diagnosed multiple by patients with MM, many are living long enough to have their myeloma patient is crucial for providing the optimal MM transform into sPCL.
    [Show full text]
  • Progression of a Solitary, Malignant Cutaneous Plasma-Cell Tumour to Multiple Myeloma in a Cat
    Case Report Progression of a solitary, malignant cutaneous plasma-cell tumour to multiple myeloma in a cat A. Radhakrishnan1, R. E. Risbon1, R. T. Patel1, B. Ruiz2 and C. A. Clifford3 1 Mathew J. Ryan Veterinary Hospital of the University of Pennsylvania, Philadelphia, PA, USA 2 Antech Diagnostics, Farmingdale, NY, USA 3 Red Bank Veterinary Hospital, Red Bank, NJ, USA Abstract An 11-year-old male domestic shorthair cat was examined because of a soft-tissue mass on the left tarsus previously diagnosed as a malignant extramedullary plasmacytoma. Findings of further diagnostic tests carried out to evaluate the patient for multiple myeloma were negative. Five Keywords hyperproteinaemia, months later, the cat developed clinical evidence of multiple myeloma based on positive Bence monoclonal gammopathy, Jones proteinuria, monoclonal gammopathy and circulating atypical plasma cells. This case multiple myeloma, pancytopenia, represents an unusual presentation for this disease and documents progression of an plasmacytoma extramedullary plasmacytoma to multiple myeloma in the cat. Introduction naemia, although it also can occur with IgG or IgA Plasma-cell neoplasms are rare in companion ani- hypersecretion (Matus & Leifer, 1985; Dorfman & mals. They represent less than 1% of all tumours in Dimski, 1992). Clinical signs of hyperviscosity dogs and are even less common in cats (Weber & include coagulopathy, neurologic signs (dementia Tebeau, 1998). Diseases represented in this category and ataxia), dilated retinal vessels, retinal haemor- of neoplasia include multiple myeloma (MM), rhage or detachment, and cardiomyopathy immunoglobulin M (IgM) macroglobulinaemia (Dorfman & Dimski, 1992; Forrester et al., 1992). and solitary plasmacytoma (Vail, 2001). These con- Coagulopathy can result from the M-component ditions can result in an excess secretion of Igs interfering with the normal function of platelets or (paraproteins or M-component) which produce a clotting factors.
    [Show full text]
  • A Case of Rare Subtype of Multiple Myeloma: Secondary Plasma Cell Leukemia Author Affiliations Are Listed at the End of This Article
    Sanwal et al. HCA Healthcare Journal of Medicine (2021) 2:1 https://doi.org/10.36518/2689-0216.1114 Case Report A Case of Rare Subtype of Multiple Myeloma: Secondary Plasma Cell Leukemia Author affiliations are listed at the end of this article. Chandra Sanwal, DO,1 Aftab Mahmood, MD,1 Michael Bailey, MD,2 Krutika Patel, MD,1 Antonio Guzman, MD1 Correspondence to: Chandra Sanwal, DO Abstract Corpus Christi Medical Description Center Plasma cell leukemia is a rare, aggressive form of multiple myeloma with the presence of 7101 S Padre Island Dr circulating plasma cells in the peripheral blood. There are two types of plasma cell leukemia, Corpus Christi, TX 78412 primary and secondary, depending on if there was previous evidence of multiple myeloma. The diagnostic criterion of plasma cell leukemia is based on a percentage (>20%) or an abso- (chandrasanwal7@gmail. lute number of (≥2 x 109/L) plasma cells in the peripheral circulation. We present the clinical com) course of a rare case of secondary plasma cell leukemia in a patient from the time of initial diagnosis of multiple myeloma, its remission period of about 5 years, and its final progres- sion into refractory secondary plasma cell leukemia. This case report details the patient’s presenting symptoms, pertinent laboratory and diagnostic imaging findings, and histopa- thology of peripheral blood and bone marrow. This case report presents a chronological comparison of key laboratory findings that manifest the progression of multiple myeloma into secondary plasma cell leukemia. It also offers a brief review of the literature for the diagnosis and treatment of plasma cell leukemia.
    [Show full text]
  • Plasmacytoma in the Oral Cavity: a Case Report
    Int. J. Odontostomat., 5(2):115-118, 2011. Plasmacytoma in the Oral Cavity: A Case Report Plasmocitoma en la Cavidad Oral: Reporte de Caso Tarley Pessoa de Barros*; Fabio Moschetto Sevilha*; Daniela Vieira Amantea*; Gabriel Denser Campolongo*; Laurindo Borelli Neto*; Nilton Alves**,*** & Reinaldo José de Oliveira* BARROS, T. P.; SAVILHA, F. M.; AMANTEA, D. V.; CAMPOLONGO, G. D.; NETO, L. B.; ALVES, N. & OLIVEIRA, R. J. Plasmacytoma in the oral cavity: A case report. Int. J. Odontostomat., 5(2):115-118, 2011. ABSTRACT: The plasma cell neoplasms may present in soft tissue as extramedullary plasmacytoma (EMP), in bone as a solitary plasmacytoma of bone (SPB), or as part of the multifocal disseminated disease multiple myeloma (MM). The EMP is rare, comprising around 3% of all plasma cell neoplasm. The majority (80%) occurs in the head and neck region. In this study we report a case of a man, 70 years old, melanoderm, with a lesion of the oral cavity. Upon physical examination, a lesion was found that extended throughout the posterior upper alveolar ridge, as far as the maxillary tuber on the left side, extending towards the palate. Radiographic examination, complementary laboratory exams were performed. Based on the conclusive symptoms of plasmacytoma, the patient was referred to the hematology service for treatment with local radiotherapy. The patient responded satisfactorily to the treatment, and after 15 months, all clinical symptoms of the lesion in the oral cavity had disappeared. KEY WORDS: plasma cell neoplasms, extramedullary plasmacytoma, bone marrow, oral cavity. INTRODUCTION The plasma cell neoplasms may present in soft consisting predominantly of plasmacytes surrounded tissue as extramedullary plasmacytoma (EMP), in bone by a fine reticular network (Nasr Ben Ammar et al., as a solitary plasmacytoma of bone (SPB), or as part 2010).
    [Show full text]
  • Hematologic Malignancies: … a Guide to the ILROG Guidelines
    Hematologic Malignancies: … A Guide to the ILROG Guidelines John P. Plastaras, MD, PhD Associate Professor February 27, 2020 Disclosures Steering Committee of ILROG, and chair the Education Committee Co-chair of the Lymphoma Committee for the American Board of Radiology ASTRO Scientific Committee (Heme, Vice-Chair) My wife is on ASTRO Board of Directors, ACGME, RRC I am receiving support from Merck (free drug) for a clinical trial we are doing at Penn Unfortunately, no financial disclosures 2 Outline What ILROG guidelines are out there? Solitary Plasmacytoma and Multiple Myeloma Low-Grade Lymphomas Hodgkin Lymphoma Insights into “Involved Site” Radiotherapy (ISRT) Treating the Mediastinum DLBCL 3 Who is making guidelines currently? National Comprehensive Cancer Network (NCCN) European Society for Medical Oncology (ESMO) Children’s Oncology Group (COG) American Radium Society (ARS) adopted the Appropriateness Criteria program from the American College of Radiology (ACR) International Lymphoma Radiation Oncology Group (ILROG) 4 ESMO Guidelines: Medical Oncology 5 ESMO Guidelines: Hematologic Diseases Waldenstrom's macroglobulinaemia Chronic myeloid leukaemia Newly diagnosed and relapsed mantle cell lymphoma Multiple myeloma Newly diagnosed and relapsed follicular lymphoma Extranodal diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma Acute lymphoblastic leukaemia Peripheral T-cell lymphomas Diffuse large B cell lymphoma Chronic lymphocytic leukaemia Hairy cell leukaemia Philadelphia chromosome-negative
    [Show full text]
  • Plasma Cell Leukemia – Facts and Controversies: More Questions Than Answers?
    Clinical Hematology International Vol. 2(4); December (2020), pp. 133–142 DOI: https://doi.org/10.2991/chi.k.200706.002; eISSN 2590-0048 https://www.atlantis-press.com/journals/chi/ Review Plasma Cell Leukemia – Facts and Controversies: More Questions than Answers? Anna Suska1, David H. Vesole2, Jorge J. Castillo3, Shaji K. Kumar4, Hari Parameswaran5, Maria V. Mateos6, Thierry Facon7, Alessandro Gozzetti8, Gabor Mikala9, Marta Szostek1, Joseph Mikhael10, Roman Hajek11, Evangelos Terpos12, Artur Jurczyszyn1,* 1Department of Hematology, Jagiellonian University Medical College, Kopernika 17, Krakow 31-501, Poland 2The John Theurer Cancer Center at Hackensack UMC, Hackensack, NJ, USA 3Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA 4Division of Hematology, Mayo Clinic, Rochester, MN, USA 5Medical College of Wisconsin, Milwaukee, WI, USA 6Complejo Asistencial Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (CAUSA/IBSAL), Salamanca, Spain 7Service des Maladies du Sang, Hôpital Claude Huriez, Lille, France 8Division of Hematology and Transplants, University of Siena, Siena, Italy 9Department of Hematology and Stem Cell Transplantation, South-Pest Central Hospital, Natl. Inst. Hematol. Infectol, Budapest, Hungary 10Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, Arizona, USA 11University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic 12Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece ARTICLE INFO ABSTRACT Article History Plasma cell leukemia (PCL) is an aggressive hematological malignancy characterized by an uncontrolled clonal proliferation of Received 07 April 2020 plasma cells (PCs) in the bone marrow and peripheral blood. PCL has been defined by an absolute number of circulating PCs Accepted 01 June 2020 exceeding 2.0 × 109/L and/or >20% PCs in the total leucocyte count.
    [Show full text]
  • Ninlaro® (Ixazomib)
    Ninlaro® (ixazomib) (Oral) Document Number: IC-0261 Last Review Date: 10/26/2020 Date of Origin: 12/04/2015 Dates Reviewed: 12/04/2015, 10/2016, 10/2017, 10/2018, 11/2019, 11/2020 I. Length of Authorization 6,7 Coverage will be provided for six months and may be renewed unless otherwise specified. Waldenström Macroglobulinemia: Initial coverage will be provided for 6 months consisting of six 4-week cycles (6 doses) and may be renewed up to a maximum of six 8-week cycles (6 doses) Systemic Light Amyloidosis: Coverage may be renewed up to a maximum of twelve 4-week cycles (12 doses) II. Dosing Limits A. Quantity Limit (max daily dose) [NDC Unit]: 2.3 mg capsule: 3 capsules per 28 days 3 mg capsule: 3 capsules per 28 days 4 mg capsule: 3 capsules per 28 days B. Max Units (per dose and over time) [HCPCS Unit]: 12 mg per 28 days III. Initial Approval Criteria 1 Coverage is provided in the following conditions: Patient is at least 18 years of age; AND Universal Criteria 1 Patient will avoid concomitant use with strong CYP3A inducers (e.g., rifampin, phenytoin, carbamazepine, St. John’s Wort, etc.); AND Multiple Myeloma† Ф 1-3 Used as initial therapy; AND Proprietary & Confidential © 2020 Magellan Health, Inc. o Used in combination with lenalidomide and dexamethasone in patients who are not transplant candidates; OR o Used in combination with cyclophosphamide and dexamethasone in patients who are transplant candidates; OR Used as maintenance therapy; AND o Used as single agent therapy in patients who are transplant candidates; AND .
    [Show full text]